vs

Side-by-side financial comparison of CareDx, Inc. (CDNA) and RadNet, Inc. (RDNT). Click either name above to swap in a different company.

RadNet, Inc. is the larger business by last-quarter revenue ($547.7M vs $108.4M, roughly 5.1× CareDx, Inc.). RadNet, Inc. runs the higher net margin — -0.1% vs -3.8%, a 3.7% gap on every dollar of revenue. On growth, CareDx, Inc. posted the faster year-over-year revenue change (25.2% vs 14.8%). Over the past eight quarters, CareDx, Inc.'s revenue compounded faster (22.7% CAGR vs 12.6%).

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

RadNet is an American radiology firm. The company operates outpatient diagnostic imaging services. Headquartered in Los Angeles, California, RadNet is the largest operator of freestanding, fixed-site diagnostic imaging centers in the United States, based on the number of locations and annual imaging revenue. As of 2025, the company owns and/or operates over 400 imaging centers across Arizona, California, Delaware, Florida, Maryland, New Jersey, New York, and Texas.

CDNA vs RDNT — Head-to-Head

Bigger by revenue
RDNT
RDNT
5.1× larger
RDNT
$547.7M
$108.4M
CDNA
Growing faster (revenue YoY)
CDNA
CDNA
+10.4% gap
CDNA
25.2%
14.8%
RDNT
Higher net margin
RDNT
RDNT
3.7% more per $
RDNT
-0.1%
-3.8%
CDNA
Faster 2-yr revenue CAGR
CDNA
CDNA
Annualised
CDNA
22.7%
12.6%
RDNT

Income Statement — Q4 2025 vs Q4 2025

Metric
CDNA
CDNA
RDNT
RDNT
Revenue
$108.4M
$547.7M
Net Profit
$-4.1M
$-597.0K
Gross Margin
Operating Margin
-5.6%
5.1%
Net Margin
-3.8%
-0.1%
Revenue YoY
25.2%
14.8%
Net Profit YoY
-104.7%
-111.2%
EPS (diluted)
$-0.08
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDNA
CDNA
RDNT
RDNT
Q4 25
$108.4M
$547.7M
Q3 25
$100.1M
$522.9M
Q2 25
$86.7M
$498.2M
Q1 25
$84.7M
$471.4M
Q4 24
$86.6M
$477.1M
Q3 24
$82.9M
$461.1M
Q2 24
$92.3M
$459.7M
Q1 24
$72.0M
$431.7M
Net Profit
CDNA
CDNA
RDNT
RDNT
Q4 25
$-4.1M
$-597.0K
Q3 25
$1.7M
$5.4M
Q2 25
$-8.6M
$14.5M
Q1 25
$-10.4M
$-37.9M
Q4 24
$87.7M
$5.3M
Q3 24
$-10.6M
$3.2M
Q2 24
$-4.6M
$-3.0M
Q1 24
$-19.9M
$-2.8M
Operating Margin
CDNA
CDNA
RDNT
RDNT
Q4 25
-5.6%
5.1%
Q3 25
-0.2%
5.2%
Q2 25
-12.8%
6.2%
Q1 25
-15.8%
-5.1%
Q4 24
97.5%
5.1%
Q3 24
-16.6%
7.4%
Q2 24
-7.9%
7.6%
Q1 24
-31.3%
2.6%
Net Margin
CDNA
CDNA
RDNT
RDNT
Q4 25
-3.8%
-0.1%
Q3 25
1.7%
1.0%
Q2 25
-9.9%
2.9%
Q1 25
-12.2%
-8.0%
Q4 24
101.3%
1.1%
Q3 24
-12.8%
0.7%
Q2 24
-5.0%
-0.6%
Q1 24
-27.6%
-0.6%
EPS (diluted)
CDNA
CDNA
RDNT
RDNT
Q4 25
$-0.08
$0.00
Q3 25
$0.03
$0.07
Q2 25
$-0.16
$0.19
Q1 25
$-0.19
$-0.51
Q4 24
$1.60
$0.08
Q3 24
$-0.20
$0.04
Q2 24
$-0.09
$-0.04
Q1 24
$-0.38
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDNA
CDNA
RDNT
RDNT
Cash + ST InvestmentsLiquidity on hand
$177.2M
$767.2M
Total DebtLower is stronger
$1.1B
Stockholders' EquityBook value
$303.1M
$1.1B
Total Assets
$413.2M
$3.8B
Debt / EquityLower = less leverage
1.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDNA
CDNA
RDNT
RDNT
Q4 25
$177.2M
$767.2M
Q3 25
$194.2M
$804.7M
Q2 25
$186.3M
$833.2M
Q1 25
$230.9M
$717.3M
Q4 24
$260.7M
$740.0M
Q3 24
$240.9M
$748.9M
Q2 24
$228.9M
$741.7M
Q1 24
$215.9M
$527.0M
Total Debt
CDNA
CDNA
RDNT
RDNT
Q4 25
$1.1B
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.0B
Q4 24
$1.0B
Q3 24
$0
$1.0B
Q2 24
$0
$1.0B
Q1 24
$834.6M
Stockholders' Equity
CDNA
CDNA
RDNT
RDNT
Q4 25
$303.1M
$1.1B
Q3 25
$311.1M
$1.1B
Q2 25
$327.4M
$932.3M
Q1 25
$379.3M
$898.1M
Q4 24
$378.4M
$902.3M
Q3 24
$273.2M
$895.3M
Q2 24
$264.7M
$881.0M
Q1 24
$256.2M
$873.0M
Total Assets
CDNA
CDNA
RDNT
RDNT
Q4 25
$413.2M
$3.8B
Q3 25
$432.3M
$3.7B
Q2 25
$444.3M
$3.5B
Q1 25
$489.6M
$3.3B
Q4 24
$491.1M
$3.3B
Q3 24
$477.0M
$3.3B
Q2 24
$466.8M
$3.2B
Q1 24
$452.4M
$3.0B
Debt / Equity
CDNA
CDNA
RDNT
RDNT
Q4 25
1.00×
Q3 25
1.04×
Q2 25
1.18×
Q1 25
1.12×
Q4 24
1.13×
Q3 24
0.00×
1.14×
Q2 24
0.00×
1.17×
Q1 24
0.96×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDNA
CDNA
RDNT
RDNT
Operating Cash FlowLast quarter
$21.4M
$84.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDNA
CDNA
RDNT
RDNT
Q4 25
$21.4M
$84.2M
Q3 25
$37.4M
$52.8M
Q2 25
$9.9M
$120.3M
Q1 25
$-26.6M
$41.5M
Q4 24
$21.9M
$42.5M
Q3 24
$12.5M
$57.4M
Q2 24
$18.9M
$116.0M
Q1 24
$-15.3M
$17.1M
Cash Conversion
CDNA
CDNA
RDNT
RDNT
Q4 25
Q3 25
22.30×
9.75×
Q2 25
8.33×
Q1 25
Q4 24
0.25×
7.96×
Q3 24
17.89×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CDNA
CDNA

Services$78.4M72%
Patient And Digital Solutions$16.8M15%
Products$13.3M12%

RDNT
RDNT

Commercial Insurance1$301.0M55%
Medicare1$129.2M24%
Capitation Arrangements$31.9M6%
Health Care Other$20.4M4%
Digital Health$16.4M3%
Other$15.2M3%
Medicaid1$14.0M3%
Workers Compensation Personal Injury1$12.3M2%
Health Care Management Service$7.5M1%

Related Comparisons